Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
1. A compound of Formula I
wherein
R 1 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 4-7 alkylcycloalkyl,
wherein the cycloalkyl in R 1 , if substituted, also in alkylcycloalkyl, is substituted with substituents selected from the group consisting of —R 4′″ , halogen, —SR 4′″ , —CN, haloalkyl, and —NR 4′″ R 4′″ ,
wherein the alkyl, alkenyl and alkynyl in R 1 , if substituted, are substituted with substituents selected from the group consisting of halogen, —CN, and haloalkyl;
R 2 is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl,
wherein the aryl or heterocyclyl in R 2 , if substituted, is substituted with substituents selected from the group consisting of —R 4 , —OR 4 , halogen, ═O, —OCH 2 CH 2 OH, —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —CN, haloalkyl, -haloalkoxy, —NR 4 R 4′″ , —NO 2 , —NR 4 C(O)R 4′ , —NR 4 SO 2 R 4′ , —C(O)OR 4 , —C(O)NR 4 R 4′ , —NR 4 C(O)NR 4′ R 4″ , —S(O) 2 NR 4 R 4′ , and —NR 4 S(O) 2 NR 4′ R 4″ ,
R 3 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 4-7 alkylcycloalkyl, substituted or unsubstituted C 4-7 alkylaryl, substituted or unsubstituted C 3-6 aryl, substituted or unsubstituted C 3-6 heterocyclyl or substituted or unsubstituted C 4-7 alkylheterocyclyl,
wherein the aryl, heterocyclyl or cycloalkyl in R 3 , if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, is substituted with substituents selected from the group consisting of —R 4 , —OR 4 , halogen, ═O, —OCH2CH2OH, —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —CN, haloalkyl, -haloalkoxy, —NR 4 R 4′″ , —NO 2 , —NR 4 C(O)R 4′ , —NR 4 S(O) 2 R 4′ , —C(O)OR 4 , —C(O)NR 4 R 4′ , —NR 4 C(O)NR 4′ R 4′″ , —S(O) 2 NR 4 R 4′ , and —NR 4 S(O) 2 NR 4′ R 4′″
and wherein the alkyl, alkenyl and alkynyl as defined in R 3 , if substituted, are substituted with substituents selected from —OR 4 , halogen, —CN, and haloalkyl,
R 3′ is hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl or unsubstituted C 2-6 alkynyl,
alternatively R 3 and R 3′ taken together with the connecting C-atom form an substituted or unsubstituted C 3-6 cycloalkyl,
wherein the cycloalkyl formed by R 3 and R 3′ taken together with the connecting C-atom, if substituted, is substituted with substituents selected from the group consisting of —R 4 , —OR 4 , halogen, ═O, —OCH 2 CH 2 OH, —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —CN, haloalkyl, -haloalkoxy, —NR 4 R 4′″ , —NO 2 , —NR 4 C(O)R 4′ , —NR 4 S(O) 2 R 4′ , —C(O)OR 4 , —C(O)NR 4 R 4′ , —NR 4 C(O)NR 4′ R 4″ , —S(O) 2 NR 4 R 4′ , and —NR 4 S(O) 2 NR 4′ R 4″ ;
R 4 , R 4′ and R 4″ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl or substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl,
wherein the cycloalkyl in R 4 , R 4′ or R 4″ , if substituted, is substituted with substituents selected from the group consisting of —R 4′″ , halogen, —SR 4′″ , —CN, haloalkyl, and —NR 4′″ R 4′″ ,
wherein the alkyl, alkenyl and alkynyl in R 4 , R 4′ or R 4″ , if substituted, are substituted with substituents selected from the group consisting of halogen, —CN, and haloalkyl;
R 4′″ is hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl or -Boc;
optionally as a stereoisomer, a racemate or in form of a mixture of at least two stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
2. The compound according to claim 1 , wherein
R 1 is unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted C 3-6 cycloalkyl, unsubstituted C 4-7 alkylcycloalkyl;
R 2 is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl,
wherein the aryl or heterocyclyl, if substituted, is substituted with substituents selected from the group consisting of —R 4 , —OR 4 , halogen, ═O, —OCH 2 CH 2 OH, —SR 4 , —S(O)R 4 , —S(O) 2 R 4 , —CN, haloalkyl -haloalkoxy, —NR 4 R 4′″ , —NO 2 , —NR 4 C(O)R 4′ , —NR 4 S(O) 2 R 4′ , —C(O)OR 4 , —C(O)NR 4 R 4′ , —NR 4 C(O)NR 4′ R 4″ , —S(O) 2 NR 4 R 4′ , and —NR 4 S(O) 2 NR 4′ R 4″ ;
R 3 is unsubstituted C 1-6 alkyl, unsubstituted C 2-5 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted C 3-6 cycloalkyl, unsubstituted C 4-7 alkylcycloalkyl, unsubstituted C 4-7 alkylaryl, unsubstituted C 3-6 aryl, unsubstituted C 3-6 heterocyclyl or unsubstituted C 4-7 alkylheterocyclyl;
R 3′ is hydrogen or unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl or unsubstituted C 2-6 alkynyl,
alternatively R 3 and R 3′ taken together with the connecting C-atom form an unsubstituted C 3-6 cycloalkyl;
R 4 , R 4′ and R 4″ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, and unsubstituted C 3-6 cycloalkyl;
R 4′″ is hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl or -Boc;
optionally as a stereoisomer, a racemate or in form of a mixture of at least two stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
3. The compound according to claim 1 , wherein the compound of formula I is a compound of formula I′
wherein q is 1, 2, 3 or 4,
optionally as a stereoisomer, a racemate or in form of a mixture of at least two stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
4. The compound according to claim 3 , wherein q is 1,
optionally as a stereoisomer, a racemate or in form of a mixture of at least two stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
5. The Compound according to claim 1 , wherein the compound of formula I is a compound of formula I″
optionally as a stereoisomer, a racemate or in form of a mixture of at least two stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
6. The compound according to claim 1 , wherein
R 1 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 4-7 alkylcycloalkyl:
R 2 is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl, wherein
the monocyclic aryl is substituted or unsubstituted phenyl; and
the monocyclic heterocyclyl is a heterocyclic ring system of one saturated or unsaturated ring which contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur;
R 3 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 cycloalkyl, substituted or unsubstituted C 4-7 alkylcycloalkyl, substituted or unsubstituted C 4-7 alkylaryl, substituted or unsubstituted C 3-6 aryl, substituted or unsubstituted C 3-6 heterocyclyl or substituted or unsubstituted C 4-7 alkylheterocyclyl; wherein
the aryl is phenyl, and
the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur;
R 3′ is hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl or unsubstituted C 2-6 alkynyl,
or R 3 and R 3′ taken together with the connecting C-atom form an substituted or unsubstituted C 3-6 cycloalkyl;
R 4 , R 4′ and R 4″ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl or substituted or unsubstituted C 2-6 alkynyl, and substituted or unsubstituted C 3-6 cycloalkyl;
R 4′″ is hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl or -Boc;
optionally as a stereoisomer, a racemate or in form of a mixture of at least two stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
7. The compound according to claim 6 , wherein
R 1 is selected from the group consisting of substituted or unsubstituted methyl, ethyl, isopropyl; substituted or unsubstituted ethenyl, propenyl, butenyl, pentenyl, or hexenyl; substituted or unsubstituted ethyne, propyne, butyne, pentyne or hexyne; and substituted or unsubstituted cyclopropyl;
R 2 is selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, thiazole, tetrahydropyran, morpholine, furan, triazole, isoxazole, pyrazole, thiophene, pyrrole, pyrazine, oxopyrrolidine, or pyrimidine;
R 3 is selected from the group consisting of substituted or unsubstituted methyl, ethyl, or isopropyl; substituted or unsubstituted ethenyl, propenyl, butenyl, pentenyl, or hexenyl; substituted or unsubstituted propyne; substituted or unsubstituted phenyl; substituted or unsubstituted imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole, oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole or quinazoline; and substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
R 3′ is selected from the group consisting of hydrogen, methyl, ethyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, ethyne, propyne, butyne, pentyne, and hexyne; or
R 3 and R 3′ taken together with the connecting C-atom form an substituted or unsubstituted cyclopropyl ring;
R 4 , R 4′ and R 4″ are independently selected from the group consisting of hydrogen; substituted or unsubstituted methyl; substituted or unsubstituted ethenyl, propenyl, butenyl, pentenyl, or hexenyl; substituted or unsubstituted ethyne, propyne, butyne, pentyne or hexyne; and substituted or unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
R 4′″ is hydrogen or -Boc.
8. The compound according to claim 6 , wherein
R 1 is unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl or unsubstituted cyclopropyl;
R 2 is substituted or unsubstituted phenyl, substituted or unsubstituted pyridine, or substituted or unsubstituted thiazole;
R 3 is substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted isopropyl, substituted or unsubstituted propyne, substituted or unsubstituted benzyl, or —CH 2 CH 2 OH;
R 3′ is hydrogen, methyl, or ethyl;
R 4 , R 4′ and R 4″ are independently selected from the group consisting of hydrogen and substituted or unsubstituted methyl;
R 4′″ is hydrogen or -Boc.
9. The compound according to claim 1 , wherein
R 1 is unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted C 3-6 cycloalkyl, unsubstituted C 4-7 alkylcycloalkyl;
R 2 is substituted or unsubstituted monocyclic aryl or substituted or unsubstituted monocyclic heterocyclyl, wherein
the aryl is phenyl and
the heterocyclyl is a heterocyclic ring system of one saturated or unsaturated ring which contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur;
R 3 is unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted C 3-6 cycloalkyl, unsubstituted C 4-7 alkylcycloalkyl, unsubstituted C 4-7 alkylaryl, unsubstituted C 3-6 aryl, unsubstituted C 3-6 heterocyclyl or unsubstituted C 4-7 alkylheterocyclyl, wherein
the aryl is phenyl;
the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur;
R 3′ is hydrogen or unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl or unsubstituted C 2-6 alkynyl;
or
R 3 and R 3′ taken together with the connecting C-atom form an unsubstituted C 3-6 cycloalkyl;
R 4 , R 4′ and R 4″ are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, and unsubstituted C 3-6 cycloalkyl;
R 4′″ is hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl or -Boc;
optionally as a stereoisomer, a racemate or in form of a mixture of at least two stereoisomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
10. The compound according to claim 9 , wherein
R 1 is methyl, ethyl, isopropyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, ethyne, propyne, butyne, pentyne, hexyne, or cyclopropyl;
R 2 is selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, thiazole, tetrahydropyran, morpholine, furan, triazole, isoxazole, pyrazole, thiophene, pyrrole, pyrazine, oxopyrrolidine, or pyrimidine;
R 3 is methyl, ethyl, isopropyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, propyne, phenyl; imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole, oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole, or cyclopropyl;
R 3′ is hydrogen, methyl, ethyl, isopropyl ethenyl, propenyl, butenyl, pentenyl, hexenyl, ethyne, propyne, butyne, pentyne, or hexyne; or
R 3 and R 3′ taken together with the connecting C-atom form a cyclopropyl or cyclopentyl ring;
R 4 , R 4′ and R 4′″ are independently selected from the group consisting of hydrogen, methyl; ethenyl, propenyl, butenyl, pentenyl, hexenyl, ethyne, propyne, butyne, pentyne, hexyne, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;
R 4′″ is hydrogen or -Boc.
11. The compound according to claim 9 , wherein
R 1 is methyl, ethyl, isopropyl, or cyclopropyl;
R 2 is substituted or unsubstituted phenyl, substituted or unsubstituted pyridine, or substituted or unsubstituted thiazole;
R 3 is methyl, ethyl, isopropyl, propyne, benzyl, or —CH 2 CH 2 OH;
R 3′ is hydrogen, methyl, or ethyl;
R 4 , R 4′ and R 4′″ are independently selected from the group consisting of hydrogen and methyl;
R 4′″ is hydrogen or -Boc.
12. The compound according to claim 1 , wherein the compound is selected from the group consisting of:
12-ethyl-8-{2-[3-(trifluoromethyl)pyridin-2-yl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-{2-[6-(trifluoromethyl)pyridin-2-yl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-[2-(3-fluoropyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-{2-[4-(trifluoromethyl)pyridin-2-yl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
8-[2-(3-chloropyridin-2-yl)ethyl]-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
8-[2-(6-aminopyridin-2-yl)ethyl]-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-isopropyl-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-isopropyl-8-[2-(pyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one dihydrochloride
12-ethyl-8-[2-(pyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
(R)-2,4-dimethyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
12-ethyl-8-{2-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-[2-(6-methoxypyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-[2-(6-hydroxypyridin-2-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)benzene-1-sulfonamide
4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)-N-methylbenzene-1-sulfonamide
12-ethyl-8-{2-[3-(trifluoromethoxy)phenyl]ethyl}-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
(R)-4-ethyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
12-ethyl-8-(3-nitrophenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-(3-methoxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
tert-butyl (4-(2-(12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)ethyl)thiazol-2-yl)carbamate
methyl 4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)benzoate
12-ethyl-8-[2-(pyridin-4-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-[2-(pyridin-3-yl)ethyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-(4-methoxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-(2-methoxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
3-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)benzonitrile
4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)-N,N-dimethylbenzamide
8-[2-fluorophenethyl]-12-methyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
8-[2-fluorophenethyl]-12-isopropyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
(R)-2-isopropyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-ethyl-9-(2-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2-ethyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(3-fluorophenethyl)-4-isopropyl-2-methyl-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-cyclopropyl-9-(2-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-isopropyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(2-fluorophenethyl)-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(3-fluorophenethyl)-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(2-fluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-cyclopropyl-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-cyclopropyl-9-(3-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-ethyl-9-(3-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
8-(3-fluorophenethyl)-12-isopropyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one hydrochloride
(R)-2,4-dimethyl-9-(3-(trifluoromethyl)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2,4-dimethyl-9-(2-(trifluoromethoxy)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(2-fluorophenethyl)-2-isopropyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(3-fluorophenethyl)-2-isopropyl-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2,4-dimethyl-9-(2-(trifluoromethyl)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(2,6-difluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(2,5-difluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(2,3-difluorophenethyl)-4-isopropyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2-ethyl-9-(2-fluorophenethyl)-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2-ethyl-9-(3-fluorophenethyl)-4-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
2,2,4-trimethyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
12-methyl-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
8-(3-aminophenethyl)-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
N-[3-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)phenyl]acetamide
[3-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)phenyl]urea
4-(2-{12-ethyl-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl}ethyl)-N-methylbenzamide
12-ethyl-8-(2-hydroxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-(3-hydroxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-(4-hydroxyphenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3] tridecan-13-one hydrochloride
8-[2-(2-aminothiazol-4-yl)ethyl]-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
2,2-diethyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
4-cyclopropyl-9-(2-fluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
8-(2,5-difluorophenethyl)-12-isopropyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
8-(2,3-difluorophenethyl)-12-isopropyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-One
10-(2-fluorophenethyl)-14-methyl-6-oxa-10,14-diazadispiro[4.1.5.3]pentadecan-15-one
10-(3-fluorophenethyl)-14-methyl-6-oxa-10,14-diazadispiro[4.1.5.3]pentadecan-15-one
(R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
8-(2,5-difluorophenethyl)-12-ethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-(3-fluorophenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
12-ethyl-8-(2-fluorophenethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one
(R)-9-(2,3-difluorophenethyl)-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2,4-diethyl-9-(2-fluorophenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2,4-diethyl-9-(3-fluorophenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2-ethyl-9-(3-fluorophenethyl)-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
4-ethyl-9-(3-fluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
4-ethyl-9-(2-fluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2-ethyl-9-(2-fluorophenethyl)-4-isopropyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(2,5-difluorophenethyl)-2,4-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
9-(3-fluorophenethyl)-4-isopropyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
9-(2-fluorophenethyl)-4-isopropyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
9-(2,3-difluorophenethyl)-4-isopropyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
4-cyclopropyl-9-(2,3-difluorophenethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
4-cyclopropyl-9-(2,5-difluorophenethyl)-22-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-9-(2,3-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
9-(2,5-difluorophenethyl)-4-ethyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
9-(2,3-difluorophenethyl)-4-ethyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
9-(2,5-difluorophenethyl)-4-isopropyl-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-cyclopropyl-9-(2,3-difluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-cyclopropyl-9-(2,5-difluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-4-methyl-9-phenethyl-2-(prop-2-yn-1-yl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
(R)-2-(2-hydroxyethyl)-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one, and
(R)-2-benzyl-4-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;
optionally in form of one of the stereoisomers, a racemate or in form of a mixture of at least two of the stereoisomers, in any mixing ratio, or a corresponding salt thereof.
13. The compound according to claim 1 , wherein the compound is in the form of an enantiomer or diastereomer.
14. The compound according to claim 1 , wherein the compound is in the form of a mixture of at least two enantiomers and/or diastereomers.
15. The compound according to claim 12 , wherein the compound is in the form of an enantiomer or diastereomer.
16. The compound according to claim 12 , wherein the compound is in the form of a mixture of at least two enantiomers and/or diastereomers.
17. A pharmaceutical composition which comprises the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
18. A method of treating pain in a subject in need thereof, comprising administration of an effective amount of the compound according to claim 1 .
19. The method according to claim 18 , wherein the pain is selected from the group consisting of medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain, neuropathic pain, allodynia, and hyperalgesia.
20. A process for the preparation of a compound of formula (I) according to claim 1 ,
which comprises the steps of
(a) reacting a compound of formula V
with a compound of formula VI
wherein W and LG are leaving groups, to obtain a compound of formula VII
(b) Carrying out a cyclisation of the resulting compound in a suitable solvent, in the presence of a strong base and at a temperature comprised between −78° C. and the reflux temperature.
21. A process for the preparation of a compound of general formula (I′) according to claim 3 :
which comprises the steps of
(a) reacting a compound of formula V
with a compound of formula XX
wherein W and LG are leaving groups, q is as defined in the preceeding claims;
to obtain a compound of formula XXI
wherein W and LG are leaving groups,
(b) carrying out a cyclisation of the resulting compound in a suitable solvent, in the presence of a strong base and at a temperature comprised between −78° C. and the reflux temperature; leading to a compound of formula XXII,
(c) and treating with a strong base, in an aprotic solvent, at a suitable temperature.